Immuntherapie beim Mammakarzinom

Article Properties
Cite
Asberger, Jasmin, et al. “Immuntherapie Beim Mammakarzinom”. Frauenheilkunde up2date, vol. 17, no. 02, 2023, pp. 193-12, https://doi.org/10.1055/a-1631-3621.
Asberger, J., Waldschmidt, J., & Rautenberg, B. (2023). Immuntherapie beim Mammakarzinom. Frauenheilkunde up2date, 17(02), 193-212. https://doi.org/10.1055/a-1631-3621
Asberger J, Waldschmidt J, Rautenberg B. Immuntherapie beim Mammakarzinom. Frauenheilkunde up2date. 2023;17(02):193-212.
Refrences
Title Journal Journal Categories Citations Publication Date
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 1,442 2017
Therapeutic vaccines for breast cancer: Has the time finally come? European Journal of Cancer
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 44 2021
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer Annals of Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 352 2021
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial 2020
Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab versus trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer 2020
Refrences Analysis
Category Category Repetition
Medicine: Medicine (General)9
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens5
Medicine: Internal medicine2
The category Medicine: Medicine (General) 9 is the most frequently represented among the references in this article. It primarily includes studies from European Journal of Cancer and New England Journal of Medicine. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year